次黄嘌呤鸟嘌呤磷酸核糖转移酶研究进展
收稿日期: 2013-01-29
修回日期: 2013-03-02
网络出版日期: 2013-08-25
基金资助
国家自然科学基金项目(编号：30471830)和深圳市科技计划重点项目(编号：201101011)资助
Research progress in hypoxanthine-guanine phosphoribosyltrans-ferase
Received date: 2013-01-29
Revised date: 2013-03-02
Online published: 2013-08-25
次黄嘌呤鸟嘌呤磷酸核糖转移酶(Hypoxanthine-guanine phosphoribosyltransferase, HPRT)是一种细胞质酶, 在体内广泛存在, 它不仅参与嘌呤碱基的补救合成途径, 而且关系到嘌呤类药物的代谢, 是调控该类药物药理效应和毒性反应的关键酶。其基因突变可影响酶的活性, 不仅可能导致不同临床表现的代谢疾病的发生, 而且影响体内嘌呤类药物的代谢。同时, HPRT作为管家基因, 是诊断许多疾病的靶点基因。文章概括了HPRT研究的新进展, 通过总结国内外研究现状, 发现HPRT的研究既推动了嘌呤类药物个体化用药的发展及新药物的研发, 又促进了HPRT突变相关遗传代谢疾病的诊断和治疗。
关键词： 次黄嘌呤鸟嘌呤磷酸核糖转移酶; 代谢疾病; 急性淋巴细胞白血病; 突变; 6-巯基嘌呤
丁慧 岳丽杰 杨春兰 . 次黄嘌呤鸟嘌呤磷酸核糖转移酶研究进展[J]. 遗传, 2013 , 35(8) : 948 -954 . DOI: 10.3724/SP.J.1005.2013.00948
Hypoxanthine-guanine phosphoribosyltransferase (HPRT) is a cytoplasmic enzyme which is widely distributed in the body. It not only involves in the purine salvage pathway, but also relates to the metabolism of purine analogues drugs. It is a critical transferase regulating the pharmacological effects and toxicity of purine analogues drugs. The mutations of the gene for HPRT, which influence its activity, may cause metabolic diseases with different clinical symptoms, and influence the metabolism of purine analogues. The HPRT gene, also a housekeeping gene, can serve diagnostic markers for many disorders. This paper reviews the recent progresses on HPRT researches in promoting the individual treatment of analogues drugs and the development of new drugs and improving the diagnosis and therapy of inherited metabolic disease caused by HPRT mutations.
[1] Kowalewska M, Danska-Bidzinska A, Bakula-Zalewska E, Bidzinski M. Identification of suitable reference genes for gene expression measurement in uterine sarcoma and car-cinosarcoma tumors. Clin Biochem, 2012, 45(4-5): 368-371.
[2] Zieliáski J, Kusy K. Training-induced adaptation in purine metabolism in high-level sprinters vs. Triathletes. J Appl Physiol, 2012, 112(4): 542-551.
[3] Hüttner E, Speit G, Lambere B, Hou SM, Holzapfel B, Tates A. European HPRT Workshop in Collaboration with GUM Gatersleben-Quedlinburg. Mutat Res, 1996, 359(1): 71-76.
[4] Duan J, Nilsson L, Lambert B. Structural and functional analysis of mutations at the human hypoxanthine phos-phoribosyl transferase (HPRT1) locus. Hum Mutat, 2004, 23(6): 599-611.
[5] Eads JC, Scapin G, Xu YM, Grubmeyer C, Sacchettini JC. The crystal structure of Human hypoxanthine- guanine phosphoribosyltransferase with bound GMP. Cell, 1994, 78(2): 325-334.
[6] Keough DT, Brereton IM, de Jersey J, Guddat LW. The crystal structure of free human hypoxanthine-guanine phosphoribosyltransferase reveals extensive conformational plasticity throughout the catalytic cycle. J Mol Biol, 2005, 351(1): 170-181.
[7] Gogia S, Balaram H, Puranik M. Hypoxanthine guanine phosphoribosyltransferase distorts the purine ring of nu-cleotide substrates and perturbs the pKa of bound xan-thosine monophosphate. Biochemistry, 2011, 50(19): 4184-4193.
[8] Boulton-Jones JR, Pritchard K, Mahmoud AA. The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment Pharmacol Ther, 2000, 14(12): 1561-1565.
[9] Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, Martin P, Vierling JM, Geller SA, Targan SR, Poordad FF. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gas-troenterology, 2003, 125(2): 298-303.
[10] Seinen ML, van Asseldonk DP, Mulder CJ, de Boer NK. Dosing 6-thioguanine in inflammatory bowel disease: expert-based guidelines for daily practice. J Gastrointestin Liver Dis, 2010, 19(3): 291-294.
[11] van Asseldonk DP, Jharap B, Kuik DJ, de Boer NK, Westerveld BD, Russel MG, Kubben FJ, van Bodegraven AA, Mulder CJ. Prolonged thioguanine therapy is well tolerated and safe in the treatment of ulcerative colitis. Dig Liver Dis, 2011, 43(2): 110-115.
[12] Bradford K, Shih DQ. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol, 2011, 17(37): 4166-4173.
[13] Jharap B, Seinen ML, de Boer NKH, van Ginkel JR, Linskens RK, Kneppelhout JC, Mulder CJJ, van Bode-graven AA. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis, 2010, 16(9): 1541-1549.
[14] Schmiegelow K, Al-Modhwahi I, Andersen MK, Behrendtz M, Forestier E, Hasle H, Heyman M, KristinssonJ, Nersting J, Nygaard R, Svendsen AL, Vettenranta K, Weinshilboum R. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Blood, 2009, 113(24): 6077-6084.
[15] De Miranda P, Beacham LM 3rd, Creagh TH, Elion GB. The metabolic fate of the methylnitroimidazole moiety of azathioprine in the rat. J Pharmacol Exp Ther, 1973, 187(3): 588-601.
[16] Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol, 1992, 43(4): 329-339.
[17] Gearry RB, Barclay ML, Roberts RL, Harraway J, Zhang M, Pike LS, George PM, Florkowski CM. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Int Med J, 2005, 35(10): 580-585.
[18] Deshpande AR, Abreu MT. Optimizing therapy with 6-mercaptopurine and azathioprine: to measure or not to measure? Therap Adv Gastroenterol, 2010, 3(5): 275-279.
/
| 〈 |
|
〉 |
www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:
